IDH MUTATION
Clinical trials for IDH MUTATION explained in plain language.
Never miss a new study
Get alerted when new IDH MUTATION trials appear
Sign up with your email to follow new studies for IDH MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to outsmart recurrent brain tumors
Disease control Recruiting nowThis Phase 2 trial tests a combination of two drugs—all-trans retinoic acid (ATRA) and retifanlimab—in people whose IDH-mutant glioma (a type of brain tumor) has returned after prior treatment. The goal is to see if the combination can boost the immune system to fight the tumor. …
Matched conditions: IDH MUTATION
Phase: PHASE2 • Sponsor: Stephen Bagley, MD, MSCE • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
New hope for bile duct cancer: drug may delay return after surgery and chemo
Disease control Recruiting nowThis study tests a drug called ivosidenib in people with a specific type of bile duct cancer (IDH1-mutated) that has been surgically removed. After standard chemotherapy, participants take ivosidenib daily to see if it helps keep the cancer from returning. The trial involves 40 a…
Matched conditions: IDH MUTATION
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC
-
New pill targets brain tumors: early trial underway
Knowledge-focused Recruiting nowThis early-phase trial is testing an oral drug called DSP-0390 in 20 people with IDH-mutant gliomas who are scheduled for tumor removal surgery. The goal is to see how much of the drug reaches the brain tumor and how it affects cholesterol-related pathways in the cancer cells. Re…
Matched conditions: IDH MUTATION
Phase: EARLY_PHASE1 • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 23, 2026 22:02 UTC
-
Glioma Patients' voices heard: radiotherapy vs. new drug in Quality-of-Life showdown
Knowledge-focused Recruiting nowThis study listens to patients with a slow-growing brain tumor (IDH-mutant grade 2 glioma) to understand how they feel during treatment. It compares two approaches: radiotherapy and a drug called vorasidenib, plus a group just being watched. The goal is to learn which treatment b…
Matched conditions: IDH MUTATION
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:05 UTC